155 related articles for article (PubMed ID: 28214592)
21. Identification of the proteomic variations of invasive relative to non-invasive non-functional pituitary adenomas.
Zhan X; Desiderio DM; Wang X; Zhan X; Guo T; Li M; Peng F; Chen X; Yang H; Zhang P; Li X; Chen Z
Electrophoresis; 2014 Aug; 35(15):2184-94. PubMed ID: 24729304
[TBL] [Abstract][Full Text] [Related]
22. Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas.
Dai C; Cai F; Hwang KC; Zhou Y; Zhang Z; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wei J; Jiao Y; Wei Z; Ma W; Wang R
Sci China Life Sci; 2013 Feb; 56(2):163-73. PubMed ID: 23334699
[TBL] [Abstract][Full Text] [Related]
23. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway.
Wang J; Zhang Z; Li R; Mao F; Sun W; Chen J; Zhang H; Bartsch JW; Shu K; Lei T
Biomed Pharmacother; 2018 Jan; 97():1066-1077. PubMed ID: 29136943
[TBL] [Abstract][Full Text] [Related]
24.
Liu P; Zhuo Z; Li W; Cheng J; Zhou H; He J; Zhang J; Wang J
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30610160
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of Invasive Nonfunctional Pituitary Adenomas by Serum Extracellular Vesicles.
Wang H; Chen K; Yang Z; Li W; Wang C; Zhang G; Zhu L; Liu P; Yang Y
Anal Chem; 2019 Aug; 91(15):9580-9589. PubMed ID: 31264409
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis of invasive non-functional pituitary adenomas using exosomal biomarkers.
Ren Y; Wang Y; Bao X; Feng M; Xing B; Lian W; Yao Y; Wang R
Clin Chim Acta; 2022 Apr; 529():25-33. PubMed ID: 35085587
[TBL] [Abstract][Full Text] [Related]
27. Increased β‑catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach.
Liu C; Wu Y; Yu S; Bai J; Li C; Wu D; Zhang Y
Mol Med Rep; 2017 Apr; 15(4):1793-1799. PubMed ID: 28260015
[TBL] [Abstract][Full Text] [Related]
28. Fibroblasts play a potential role in bone destruction via osteopontin related caldesmon expression and polymerization in human non-functioning pituitary adenomas.
Zhang LY; Ge XL; Li Z; Tang YJ; Xiong YY; Li XJ; Liu JF; Wanggou SY; Li CT; Yang K; Chen X; Hu ZL; Liu YS; Liu ZX
Sci Rep; 2017 Dec; 7(1):17523. PubMed ID: 29235490
[TBL] [Abstract][Full Text] [Related]
29. Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis.
Xiao JQ; Liu XH; Hou B; Yao Y; Deng K; Feng M; Xing B; Lian W; Wang RZ; Feng F
PLoS One; 2014; 9(3):e90396. PubMed ID: 24594688
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.
Hosseinkhan N; Honardoost M; Emami Z; Cheraghi S; Hashemi-Madani N; Khamseh ME
Endocrine; 2022 Sep; 77(3):500-509. PubMed ID: 35711030
[TBL] [Abstract][Full Text] [Related]
31. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas.
Feng J; Yu SY; Li CZ; Li ZY; Zhang YZ
Mol Cell Endocrinol; 2016 Nov; 436():195-203. PubMed ID: 27465831
[TBL] [Abstract][Full Text] [Related]
32. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
33. The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma.
Altaş M; Bayrak OF; Ayan E; Bolukbasi F; Silav G; Coskun KK; Culha M; Sahin F; Sevli S; Elmaci I
Acta Neurochir (Wien); 2010 Sep; 152(9):1611-7; discussion 1617. PubMed ID: 20437278
[TBL] [Abstract][Full Text] [Related]
34. Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.
Ghadir M; Khamseh ME; Panahi-Shamsabad M; Ghorbani M; Akbari H; Mehrjardi AZ; Honardoost M; Jafar-Mohammadi B
Endocrine; 2020 Sep; 69(3):596-603. PubMed ID: 32656696
[TBL] [Abstract][Full Text] [Related]
35. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
Nishioka H; Inoshita N
Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors.
McCabe CJ; Boelaert K; Tannahill LA; Heaney AP; Stratford AL; Khaira JS; Hussain S; Sheppard MC; Franklyn JA; Gittoes NJ
J Clin Endocrinol Metab; 2002 Sep; 87(9):4238-44. PubMed ID: 12213878
[TBL] [Abstract][Full Text] [Related]
37. Association of
Liao F; Yuan L; Zhu J; Chen W; Zhao Y; He J
Biomed Res Int; 2022; 2022():2712808. PubMed ID: 35996546
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas.
Zhan X; Wang X; Long Y; Desiderio DM
BMC Med Genomics; 2014 Dec; 7():69. PubMed ID: 25539738
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis of pituitary adenomas: a review.
Suhardja AS; Kovacs KT; Rutka JT
Acta Neurochir (Wien); 1999; 141(7):729-36. PubMed ID: 10481784
[TBL] [Abstract][Full Text] [Related]
40. Correlation between SPARC (Osteonectin) expression with immunophenotypical and invasion characteristics of pituitary adenomas.
Onoz M; Basaran R; Gucluer B; Isik N; Kaner T; Sav A; Elmaci I
APMIS; 2015 Mar; 123(3):199-204. PubMed ID: 25556322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
